Signal
FLT-PET as predictive non-invasive biomarker for neoadjuvant therapy with Wee1 and ATR inhibitors
The contribution of neoantigen-specific T cells to PD-(L)1 efficacy has largely been inferred from tumor mutational burden.
rss
flt
Evidence locked
Today's free sample is only available for the edition's flagship signal.
Evidence preview
- FLT-PET as predictive non-invasive biomarker for neoadjuvant therapy with Wee1 and ATR inhibitorsbioRxiv (all subjects)
- Extracellular vesicles proteomics-based machine-learning model predicts immunotherapy response in NSCLCmedRxiv (all subjects)
- Systemic neoantigen-specific T cells reveal central determinants of PD-(L)1 blockade efficacybioRxiv (all subjects)